BRISTOL MYERS SQUIBB

Incyte has appointed Bill Meury as its new CEO, effective immediately, replacing Hervé Hoppenot who led the cancer and blood disease drugmaker for 11 years.

Cigna filed a federal lawsuit against Bristol Myers Squibb, alleging the company used anti-competitive strategies to maintain a monopoly on Pomalyst, a multiple myeloma treatment that generated $2.7 billion in U.S. sales last year.

Denovo Biopharma has granted exclusive rights to develop and commercialize DB104 (liafensine) in Taiwan to Chuang Yi Global Asset Management Co., Ltd.

Prothena Corporation announced a 63% workforce reduction to substantially reduce operating costs while maintaining support for remaining wholly owned programs and partnered collaborations.

Climb Bio appointed Edgar D. Charles, M.D., MSc as Chief Medical Officer, bringing over 20 years of immunology-focused pharmaceutical development experience from Bristol Myers Squibb and Merck & Co.

Draig Therapeutics launched with $140 million in Series A funding to develop next-generation treatments for neuropsychiatric disorders, marking the largest commercial investment in Welsh research to date.

Lisocabtagene maraleucel (liso-cel) demonstrated a 95.5% overall response rate and 62.1% complete response rate in 66 patients with relapsed/refractory marginal zone lymphoma in the TRANSCEND FL trial.

Bristol Myers Squibb presented updated clinical findings on investigational CELMoD agents mezigdomide and iberdomide for multiple myeloma, and golcadomide for non-Hodgkin lymphoma at the 2025 European Hematology Association Annual Congress.

A new comprehensive report analyzes 943 autoimmune collaboration and licensing deals from 2016-2025, covering over 30 diseases including multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease.

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.